B细胞激活因子
免疫学
狼疮性肾炎
医学
肾病
体液免疫
免疫系统
系统性红斑狼疮
自身免疫性疾病
自身免疫
类风湿性关节炎
B细胞
抗体
布利西比莫德
红斑狼疮
内科学
疾病
内分泌学
糖尿病
作者
Jingjing Cai,Dan Gao,Dongwei Li,Zhangsuo Liu
标识
DOI:10.3389/fimmu.2023.1169084
摘要
B cells and the humoral immunity are important players in the pathogenesis of autoimmune diseases. BAFF (also known as BLYS) and a proliferation-inducing ligand APRIL are required for the maintenance of the B-cell pool and humoral immunity. BAFF and APRIL can promote B-cell differentiation, maturation, and plasma cell antibody secretion. BAFF/APRIL overexpression has been identified in several autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, IgA nephropathy, etc. Telitacicept, a novel fully human TACI-Fc fusion protein that binds both BAFF and APRIL, was approved in China in March 2021 for the treatment of systemic lupus erythematosus at a recommended dose of 160 mg/w subcutaneously and is in clinical trials for the treatment of multiple indications in other autoimmune diseases. In this review, we explored telitacicept's mechanism of action and clinical data. In addition, the immune features of autoimmune nephropathy were discussed, emphasizing lupus nephritis, IgA nephropathy, and membranous nephropathy.
科研通智能强力驱动
Strongly Powered by AbleSci AI